A5100388168- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- BRCA gene mutations in cancer
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Atmospheric chemistry and aerosols
- Cancer-related Molecular Pathways
- Cancer Risks and Factors
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cancer Mechanisms and Therapy
- Per- and polyfluoroalkyl substances research
- Lung Cancer Treatments and Mutations
- Microtubule and mitosis dynamics
- Cancer Diagnosis and Treatment
- Toxic Organic Pollutants Impact
- Multiple and Secondary Primary Cancers
Theranostics (New Zealand)
2015-2023
Guangdong Academy of Medical Sciences
2023
Southern Medical University
2023
Guangdong Provincial People's Hospital
2023
Hologic (United States)
2023
Army Medical University
2022-2023
Southwest Hospital
2023
Biothera (United States)
2018-2021
Sun Yat-sen University
2021
The First Affiliated Hospital, Sun Yat-sen University
2021
Abstract Background: The landmark Suppression of Ovarian Function Trial (SOFT) in premenopausal breast cancer patients revealed that the addition ovarian function suppression (OFS) to adjuvant endocrine therapy with either tamoxifen (T+OFS) or exemestane (E+OFS) reduces risk recurrence compared alone. benefit from OFS was most clinically meaningful for at higher clinico-pathologic recurrence. There are no biomarkers aid decision-making about intensification and its resultant toxicities....
555 Background: Identification of N+ breast cancer patients with a limited risk recurrence improves selection those for which chemotherapy and/or extended endocrine therapy (EET) may be most appropriate to reduce overtreatment. BCIN+ integrates gene expression tumor size and grade, is highly prognostic overall (0-10yr) late (5-10yr) distant (DR) in N1 patients. Clinical Treatment Score post-5-years (CTS5) model based on clinicopathological factors (nodes, age, grade) significantly DR. The...
512 Background: For postmenopausal women with hormone receptor positive (HR+) breast cancer, the optimal duration of extended endocrine therapy (EET), after completing 5 years initial aromatase inhibitor (AI)–based adjuvant therapy, remains unclear. BCI [HOXB13/IL17BR (H/I)] is a gene expression-based biomarker that has been demonstrated to predict EET benefit in MA.17 and Trans-aTTom studies patients treated tamoxifen. The current study examined ability (H/I) from 2.5 vs. letrozole IDEAL...
Abstract Background: BCI is a genomic signature that significantly predicts risk of both early (0-5 years) and late (5-10 distant recurrence (DR) in hormonal receptor-positive, lymph node negative (LN-) breast cancer. In LN- disease, tumor size (TS) grade (TG) are important independent prognostic factors cancer recurrence. this analysis, the effect integrating these traditional clinicopathological on ability to predict was evaluated translational arm Arimidex, Tamoxifen, Alone or Combination...
Abstract Background: The Breast Cancer Index (BCI) is a validated gene expression assay that provides quantitative individualized risk of late recurrence and predicts the likelihood benefit from extended endocrine therapy (EET) in HR+ early-stage breast cancer. objective this analysis was to assess impact BCI on clinical decision-making regarding EET Registry Study. Methods: Study an ongoing, prospective, large-scale study investigate long-term outcome, decision impact, medication adherence...
516 Background: An increasing body of evidence from extended endocrine therapy trials underscores the unmet need to manage risk-benefit at individual patient (pt) level. Breast Cancer Index (BCI) is a multigene assay that identified women with 4.8%-6.6% low risk cumulative recurrence (0-10y) and late 2.5%-3.5% in validation studies. In this post-hoc analysis, an optimized threshold identify patients favorable long-term breast cancer–specific survival was developed characterized. Methods:...
Abstract Background: For patients with early stage, hormone receptor positive (HR+) breast cancer, extension of endocrine therapy beyond 5 years reduces the ongoing risk late distant recurrence and new primary cancer but is associated potentially serious toxicities side effects that can impair quality life. While stratification by clinicopathological factors prognostic biomarkers recommended to guide patient selection, predictive are directly informative therapeutic response critical for...
531 Background: The IDEAL trial randomized hormone receptor-positive (HR+) breast cancer patients to 5 vs 2.5y of extended letrozole after completion 5y adjuvant endocrine therapy. In the parent trial, approximately 60% overall were compliant with treatment (59% 74% compliance in and arms, respectively), patient experiences as most significant factors leading discontinuation. Breast Cancer Index is a gene expression-based signature that predicts which HR+ are likely benefit from therapy...